Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.52+0.03 (+2.01%)
Close on Nov 12, 2026Market cap $6.80MP/E –Yield –
Enveric Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
Enveric Biosciences's gross margin for the twelve months ending Sep 30, 2020 was 20.7%. For fiscal 2019 it was 20.4%, against 20.9% the year before. The highest annual figure on record is 33.9% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 20.4% | −0.5 |
| FY2018 | Dec 31, 2018 | 20.9% | −0.2 |
| FY2017 | Dec 31, 2017 | 21.1% | +1.9 |
| FY2016 | Dec 31, 2016 | 19.2% | −14.7 |
| FY2015 | Dec 31, 2015 | 33.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | 22.3% | +1.5 |
| Q2 FY2020 | Jun 30, 2020 | 22.0% | +0.4 |
| Q1 FY2020 | Mar 31, 2020 | 19.6% | −0.4 |
| Q4 FY2019 | Dec 31, 2019 | 19.1% | +0.5 |
| Q3 FY2019 | Sep 30, 2019 | 20.8% | −1.4 |
| Q2 FY2019 | Jun 30, 2019 | 21.6% | +0.1 |
| Q1 FY2019 | Mar 31, 2019 | 20.0% | −1.2 |
| Q4 FY2018 | Dec 31, 2018 | 18.5% | +0.7 |
| Q3 FY2018 | Sep 30, 2018 | 22.2% | +1.7 |
| Q2 FY2018 | Jun 30, 2018 | 21.6% | +2.6 |
| Q1 FY2018 | Mar 31, 2018 | 21.2% | −5.6 |
| Q4 FY2017 | Dec 31, 2017 | 17.8% | +1.1 |
| Q3 FY2017 | Sep 30, 2017 | 20.5% | +3.6 |
| Q2 FY2017 | Jun 30, 2017 | 19.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 26.8% | – |
| Q4 FY2016 | Dec 31, 2016 | 16.7% | – |
| Q3 FY2016 | Sep 30, 2016 | 16.9% | – |
See a number that looks wrong?